Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2025.
Financials
Financial year 2025
CEREPHARMA from Ath, company number BE0834075086, closed financial year 2025 with a result of € 91,805 after tax. For that financial year CEREPHARMA recorded a gross margin of € 572,300 and equity of € 933,614. Compared with financial year 2024, the result moved from € 56,289 to € 91,805. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 933,614
▲ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 91,805
▲ 63% vs 2024
Profit after tax over the fiscal year.
€ 182,832
▼ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 168,614.
People and assets in 2025
6.3
Average over the fiscal year, from the social balance sheet.
€ 303,564
▲ 29% vs 2024
€ 48,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 36,603
▲ 23% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 230,371
▼ 20% vs 2024
€ 55,574 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 113,942
▼ 8% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 73,402
▲ 142% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 445,710 | € 477,868 | € 430,346 | € 572,300 | ▲ 33% |
| Profit after taxes | € 129,784 | € 175,839 | € 56,289 | € 91,805 | ▲ 63% |
| Equity | € 609,681 | € 785,520 | € 841,809 | € 933,614 | ▲ 11% |
| Total debts | € 966,781 | € 745,226 | € 708,850 | € 590,801 | ▼ 17% |
| Cash | € 174,494 | € 36,477 | € 231,047 | € 182,832 | ▼ 21% |
| Land & buildings | € 592,372 | € 559,655 | € 531,828 | € 506,374 | ▼ 5% |
| Retained profit | € -155,319 | € 20,520 | € 76,809 | € 168,614 | ▲ 120% |
| Bank debt | € 403,205 | € 341,590 | € 289,492 | € 230,371 | ▼ 20% |
| Balance sheet total | € 1,576,462 | € 1,530,746 | € 1,550,659 | € 1,524,415 | ▼ 2% |
| Employees (FTE) | - | - | - | 6.3 |
Key figures of CEREPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to CEREPHARMA?
What happened at CEREPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Bernard CAMBIER stepped down as director. NBB
- Anne-Sophie DE WULF stepped down as director. NBB
- Florence CAMBIER stepped down as director. NBB
- Corrected annual accounts filed for financial year 2025. filed late Source: NBB ↗
- Florence CAMBIER became a director. NBB
- New establishment in Ath. KBO
- Start of the company according to the CBE. KBO
In short
From € 129,784 profit in 2022 to € 91,805 profit in 2025.
Paid € 92,892 in corporate taxes since 2022.
Best year ever: 2023, with € 175,839 profit.
On average € 90,800 of value added per employee in 2025.
A new publication or filing at CEREPHARMA? We notify you, reason included.
Follow CEREPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Bernard CAMBIER, Anne-Sophie DE WULF, Alexandre CAMBIER and Florence CAMBIER.
Directors
According to the 2025 annual accounts
Bernard CAMBIER
Managing director
Is a shareholder
Also active at: DR. BERNARD CAMBIER, PHARMACOSMEDICS
· until 2029
· until 2029
Florence CAMBIER
Director
Is a shareholder
since 2022 · until 2029
Shareholders
Bernard CAMBIER · director
Anne-Sophie DE WULF · director
Alexandre CAMBIER
Florence CAMBIER · director
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue des Journaliers(GHI) 15
7822 Ath
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0834.075.086
- VAT number
- BE 0834.075.086
- Registered office
- Rue des Journaliers(GHI) 15, 7822 Ath
- Names & denominations
- CEREPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 25 February 2011
- Peppol
- Active · Active since 24 Nov 2023
- Contact
- [email protected] 0478/49.50.85
- Activities · NACE
Vervaardiging van parfums en toiletartikelen
Vervaardiging van overige farmaceutische producten
Detailhandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Vervaardiging van farmaceutische grondstoffen